腺病毒基因组中 Toll 样受体 9 激动剂基序的数量与腺病毒免疫复合物诱导树突状细胞成熟有关。
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
机构信息
Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland.
出版信息
J Virol. 2012 Jun;86(11):6279-85. doi: 10.1128/JVI.00123-12. Epub 2012 Apr 4.
Abstract
Adenovirus serotype 5 (Ad5) vectors and specific neutralizing antibodies (NAbs) generate immune complexes (ICs) which are potent inducers of dendritic cell (DC) maturation. Here we show that ICs generated with rare Ad vector serotypes, such as Ad26 and Ad35, which are lead candidates in HIV vaccine development, are poor inducers of DC maturation and that their potency in inducing DC maturation strongly correlated with the number of Toll-like receptor 9 (TLR9)-agonist motifs present in the Ad vector's genome. In addition, we showed that antihexon but not antifiber antibodies are responsible for the induction of Ad IC-mediated DC maturation.
摘要
腺病毒血清型 5（Ad5）载体和特定的中和抗体（NAb）会产生免疫复合物（IC），这些复合物是树突状细胞（DC）成熟的有效诱导剂。在这里，我们发现，在 HIV 疫苗开发中作为主要候选者的罕见腺病毒载体血清型（如 Ad26 和 Ad35）产生的 IC 对 DC 成熟的诱导作用较弱，其诱导 DC 成熟的效力与腺病毒载体基因组中存在的 Toll 样受体 9（TLR9）激动剂序列的数量密切相关。此外，我们还表明，抗六邻体而不是抗纤维抗体负责诱导 Ad IC 介导的 DC 成熟。
相似文献
1
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.腺病毒基因组中 Toll 样受体 9 激动剂基序的数量与腺病毒免疫复合物诱导树突状细胞成熟有关。
J Virol. 2012 Jun;86(11):6279-85. doi: 10.1128/JVI.00123-12. Epub 2012 Apr 4.
2
Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5.一种新型腺病毒血清型35载体疫苗的研发，该疫苗在腺病毒血清型5的纤维钮以及E4区的orf 4、6和6/7区域含有RGD肽。
Int J Pharm. 2024 Sep 5;662:124480. doi: 10.1016/j.ijpharm.2024.124480. Epub 2024 Jul 20.
3
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.重组腺病毒血清型 26（Ad26）和 Ad35 疫苗载体绕过对 Ad5 的免疫反应，保护非人灵长类动物免受埃博拉病毒的挑战。
J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.
4
Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.髓样和浆细胞样树突状细胞对重组腺病毒载体敏感，并能刺激多功能记忆T细胞反应。
J Immunol. 2007 Aug 1;179(3):1721-9. doi: 10.4049/jimmunol.179.3.1721.
5
Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.腺病毒血清型 5 特异性中和抗体针对多个六邻体超变区。
J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.
6
Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.腺病毒血清型 5 中和抗体在接种疫苗和自然感染后靶向六邻体和纤维。
J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.
7
Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.三聚体 knob 蛋白可特异性区分针对不同人类腺病毒种的中和抗体：腺病毒血清流行病学的潜在应用。
J Gen Virol. 2014 Jul;95(Pt 7):1564-1573. doi: 10.1099/vir.0.064832-0. Epub 2014 Apr 24.
8
Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.腺病毒-抗体复合物导致基因治疗试验中致命性全身炎症。
Mol Ther. 2020 Mar 4;28(3):784-793. doi: 10.1016/j.ymthe.2020.01.006. Epub 2020 Feb 7.
9
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.用于基因转移和疫苗接种的复制缺陷型人35型腺病毒载体：高效感染人细胞并绕过预先存在的腺病毒免疫力。
J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003.
10
Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.腺病毒5型免疫复合物激活树突状细胞- T细胞轴，为HIV在T细胞中的复制创造了更有利的环境。
J Exp Med. 2008 Nov 24;205(12):2717-25. doi: 10.1084/jem.20081786. Epub 2008 Nov 3.
引用本文的文献
1
Comparative analysis of the impact of 40 adenovirus types on dendritic cell activation and CD8 T cell proliferation capacity for the identification of favorable immunization vector candidates.比较分析 40 种腺病毒类型对树突状细胞激活和 CD8 T 细胞增殖能力的影响，以鉴定有利的免疫载体候选物。
Front Immunol. 2023 Oct 17;14:1286622. doi: 10.3389/fimmu.2023.1286622. eCollection 2023.
2
The use of adenoviral vectors in gene therapy and vaccine approaches.腺病毒载体在基因治疗和疫苗方法中的应用。
Genet Mol Biol. 2022 Oct 7;45(3 Suppl 1):e20220079. doi: 10.1590/1678-4685-GMB-2022-0079. eCollection 2022.
3
Human Adenovirus Species D Interactions with Corneal Stromal Cells.人腺病毒 D 种与角膜基质细胞的相互作用。
Viruses. 2021 Dec 14;13(12):2505. doi: 10.3390/v13122505.
4
IgG-Complexed Adenoviruses Induce Human Plasmacytoid Dendritic Cell Activation and Apoptosis.IgG- 复合腺病毒诱导人浆细胞样树突状细胞的激活和凋亡。
Viruses. 2021 Aug 27;13(9):1699. doi: 10.3390/v13091699.
5
Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.三种腺病毒载体类型在 Friend 逆转录病毒感染模型中的疫苗效力比较评估。
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01155-19. Print 2019 Nov 1.
6
Impact of dynamin 2 on adenovirus nuclear entry.动力蛋白 2 对腺病毒核内进入的影响。
Virology. 2019 Mar;529:43-56. doi: 10.1016/j.virol.2019.01.008. Epub 2019 Jan 10.
7
Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells.免疫复合物型腺病毒在人树突状细胞中诱导AIM2介导的细胞焦亡。
PLoS Pathog. 2016 Sep 16;12(9):e1005871. doi: 10.1371/journal.ppat.1005871. eCollection 2016 Sep.
8
Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.新型腺病毒载体的研发以克服基于人5型腺病毒构建体所观察到的挑战。
Mol Ther. 2016 Feb;24(1):6-16. doi: 10.1038/mt.2015.194. Epub 2015 Oct 19.
9
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.抗原表达决定腺病毒疫苗效力，与干扰素和STING信号传导无关。
J Clin Invest. 2015 Mar 2;125(3):1129-46. doi: 10.1172/JCI78280. Epub 2015 Feb 2.
10
Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells.在人类细胞中，cGAS/STING 依赖性抗病毒反应激活后腺病毒复制仍未减弱。
J Virol. 2014 Dec;88(24):14426-39. doi: 10.1128/JVI.02608-14. Epub 2014 Oct 8.
本文引用的文献
1
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.人腺病毒特异性 T 细胞调节 HIV 特异性 T 细胞对 Ad5 载体 HIV-1 疫苗的反应。
J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.
2
Rare serotype adenoviral vectors for HIV vaccine development.用于 HIV 疫苗开发的罕见血清型腺病毒载体。
J Clin Invest. 2012 Jan;122(1):25-7. doi: 10.1172/JCI60988. Epub 2011 Dec 27.
3
Modulation of human memory T-cell function by different antigen-presenting cells.不同抗原呈递细胞对人类记忆性T细胞功能的调节
Eur J Immunol. 2012 Mar;42(3):799-802. doi: 10.1002/eji.201142094. Epub 2011 Dec 20.
4
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.儿童和成人人群中腺病毒血清型 5、26、35 和 48 的国际血清流行病学研究。
Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.
5
Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.腺病毒 35 型载体通过与 CD46 的结合阻断人 CD4+T 细胞的激活。
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7499-504. doi: 10.1073/pnas.1017146108. Epub 2011 Apr 18.
6
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.重组腺病毒血清型 26（Ad26）和 Ad35 疫苗载体绕过对 Ad5 的免疫反应，保护非人灵长类动物免受埃博拉病毒的挑战。
J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.
7
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.HIV-1 利用 TLR8 和 DC-SIGN 固有信号促进树突状细胞的感染。
Nat Immunol. 2010 May;11(5):419-26. doi: 10.1038/ni.1858. Epub 2010 Apr 4.
8
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.人类腺病毒（Ad）5 型、6 型、26 型和 36 型预先存在的中和抗体的国际流行病学：与高 Ad5 滴度相关的因素及其对潜在 HIV 疫苗试验的影响。
Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.
9
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.HIV-1疫苗诱导的概念验证性初步研究中的免疫：病例队列分析
Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.
10
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.一种细胞介导免疫HIV-1疫苗的疗效评估（STEP研究）：一项双盲、随机、安慰剂对照的概念验证试验。
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
Zotero 插件